AbCellera Biologics Inc. splits its revenue into 3 lines in its filings. The largest line in Q2 of fiscal 2026, the quarter ended Jun 30, 2026 was Research Fees at $3.9 million, 96% of the total.
USD in millions. The percent under a figure is the change from the same quarter a year earlier.
| Line |
TTM
Jun 30, 2026
|
Q2 FY2026
Jun 30, 2026
|
Q1 FY2026
Mar 31, 2026
|
Q4 FY2025
Dec 31, 2025
|
Q3 FY2025
Sep 30, 2025
|
Q2 FY2025
Jun 30, 2025
|
Q1 FY2025
Mar 31, 2025
|
Q4 FY2024
Dec 31, 2024
|
Q3 FY2024
Sep 30, 2024
|
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
66
|
4
|
8
|
45
|
9
|
17
|
4
|
5
|
7
|
| Research Fees |
29
+31.1%
share 43.1%
|
4
-41.2%
share 96.3%
|
8
+99.7%
share 97.7%
|
8
+61.2%
share 17.1%
|
9
+40.2%
share 98.5%
|
7
share 38.9%
|
4
share 96.1%
|
5
share 94.4%
|
6
share 96.6%
|
| Licensing And Royalty Revenue |
37
+229.8%
share 55.4%
|
0
-98.6%
share 3.7%
|
0
+14.4%
share 2.3%
|
36
+12725.9%
share 80.6%
|
0
-36.7%
share 1.5%
|
10
share 61.1%
|
0
share 3.9%
|
0
share 5.6%
|
0
share 3.4%
|
| Milestone Payments |
—
|
—
|
—
|
—
|
—
|
—
|
—
|
0
share 0.0%
|
—
|
How these figures are calculated
Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ABCL (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- British Columbia, Canada
- Headquarters
- Vancouver, British Columbia, Canada
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1703057
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.